Carney Complex

Mendelian MONDO:0015285 Pathograph 8 Show in embeddings browser hereditary cancer-predisposing syndrome

Carney complex is an autosomal dominant multiple neoplasia syndrome defined by the combination of spotty skin pigmentation (lentigines and blue naevi), cardiac and extracardiac myxomas, endocrine overactivity, and psammomatous melanotic schwannoma. Most cases are caused by germline inactivating variants in PRKAR1A at 17q22-24, encoding the type I-alpha regulatory subunit (RIalpha) of protein kinase A; a second locus at 2p16 accounts for the remainder. Mechanistically the syndrome is a tumor suppressor two-hit disorder in which the suppressor is a brake on a second-messenger pathway rather than on the cell cycle. RIalpha binds and inhibits the PKA catalytic subunits until cyclic AMP displaces it; losing RIalpha therefore does not raise basal kinase activity so much as remove the restraint on cAMP-stimulated activity, and this is what measurement in Carney complex tumours shows — decreased basal PKA activity but increased cAMP-stimulated activity relative to non-Carney tumours. That signature explains the syndrome's most distinctive clinical trait, the paradoxical responses to endocrine signals seen in primary pigmented nodular adrenocortical disease, where dexamethasone raises rather than suppresses cortisol. Two-hit architecture is directly evidenced: loss of heterozygosity in the vicinity of PRKAR1A in 17q-linked families is what localized the gene. Cardiac myxoma is the principal cause of death and can occur at any age and in any chamber, which drives lifelong echocardiographic surveillance.

Ask OpenScientist

Ask a research question about Carney Complex. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
4
Pathophys.
6
Phenotypes
8
Pathograph
1
Genes
3
Medical Actions
1
Trials
1
References
👪

Inheritance

1
Autosomal dominant HP:0000006
Carney complex is inherited as an autosomal dominant trait with variable expressivity: which components of the complex appear differs between families and between affected members of one family, and at least two loci are involved. Sporadic cases arising from de novo variants are well documented.
Autosomal dominant inheritance Penetrance: INCOMPLETE Expressivity: VARIABLE
Show evidence (3 references)
PMID:10973256 SUPPORT Human Clinical
"CNC is inherited as an autosomal dominant trait and the genes responsible have been mapped to 2p16 and 17q22-24 (refs 6, 7)."
States the inheritance pattern and the genetic heterogeneity of the syndrome.
PMID:20301463 SUPPORT Other
"Approximately 70% of individuals diagnosed with CNC have an affected parent; approximately 30% have a de novo pathogenic variant."
GeneReviews Genetic Counseling section. The de novo rate is high enough that a negative family history carries little weight against the diagnosis. Evidence source is OTHER because GeneReviews is an expert-authored review rather than a primary study.
PMID:20301463 SUPPORT Other
"Each child of an individual with CNC has a 50% chance of inheriting the pathogenic variant."
GeneReviews Genetic Counseling section: the transmission risk to offspring.

Pathophysiology

4
Germline PRKAR1A First-Hit Inactivation
A heterozygous inactivating variant in PRKAR1A, encoding the PKA type I-alpha regulatory subunit RIalpha, is present constitutionally. Candidate-gene reasoning arrived at cyclic-nucleotide signalling before the gene was found, from the syndrome's resemblance to McCune-Albright syndrome and from its paradoxical endocrine responses. An identical coding-region variant was found in three unrelated kindreds and again in a sporadic case, with distinct variants in further families including one with isolated inherited cardiac myxomas.
PRKAR1A hgnc:9388 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves decreased PRKAR1A (hgnc:9388). hgnc:9388 is a gene from the HUGO Gene Nomenclature Committee. ↓ DECREASED
Genetic context PRKAR1A hgnc:9388 HUGO Gene Nomenclature Committee (hgnc) Relation: this genetic context concerns this gene This genetic context concerns PRKAR1A (hgnc:9388). hgnc:9388 is a gene from the HUGO Gene Nomenclature Committee. variant_origin: GERMLINE allelic_hit_role: FIRST_HIT allelic_event: PATHOGENIC_VARIANT zygosity: HETEROZYGOUS functional_impact_category: LOSS_OF_FUNCTION
Constitutional heterozygous inactivating PRKAR1A variant; a recurrent coding-region variant was shared by three unrelated kindreds and one sporadic case.
Show evidence (2 references)
PMID:10973256 SUPPORT Human Clinical
"We subsequently identified three unrelated kindreds with an identical mutation in the coding region of PRKAR1A."
Identifies the recurrent germline PRKAR1A lesion in Carney complex families.
PMID:10973256 SUPPORT Human Clinical
"We conclude that germline mutations in PRKAR1A, an apparent tumour-suppressor gene, are responsible for the CNC phenotype in a subset of patients with this disease."
Establishes PRKAR1A as a tumor suppressor and the cause of the syndrome in a subset of patients, which places this disorder in the two-hit class. Note the authors' own qualifiers ("apparent", "a subset") are preserved.
Somatic PRKAR1A Second-Hit Loss of Heterozygosity
Tumors from 17q-linked Carney complex families show loss of heterozygosity in the vicinity of PRKAR1A, including at a polymorphic site in its 5' region. Detecting that loss is what localized the gene, and it is the direct evidence that the syndrome follows the classical two-hit architecture rather than acting through haploinsufficiency alone.
Genetic context PRKAR1A hgnc:9388 HUGO Gene Nomenclature Committee (hgnc) Relation: this genetic context concerns this gene This genetic context concerns PRKAR1A (hgnc:9388). hgnc:9388 is a gene from the HUGO Gene Nomenclature Committee. variant_origin: SOMATIC allelic_hit_role: SECOND_HIT allelic_event: LOSS_OF_HETEROZYGOSITY functional_impact_category: LOSS_OF_FUNCTION
Acquired loss of heterozygosity at the PRKAR1A locus in Carney complex tumor tissue.
Show evidence (1 reference)
PMID:10973256 SUPPORT Human Clinical
"In CNC families mapping to 17q, we detected loss of heterozygosity (LOH) in the vicinity of the gene (PRKAR1A) encoding protein kinase A regulatory subunit 1-alpha (RIalpha), including a polymorphic site within its 5' region."
The direct demonstration of somatic loss of heterozygosity at the locus, which is the second hit this node asserts.
Loss of RIalpha Restraint on cAMP-Stimulated PKA Signaling
The rate-limiting state. RIalpha holds the PKA catalytic subunits inactive until displaced by cyclic AMP; losing it therefore changes the shape of the response rather than simply raising output. Carney complex tumours show decreased basal PKA activity but increased cAMP-stimulated activity relative to non-Carney tumours — an inversion of the normal relationship between stimulus and kinase output that is the biochemical correlate of the syndrome's paradoxical endocrine responses.
cAMP-dependent protein kinase regulator activity GO:0008603 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves cAMP-dependent protein kinase regulator activity (GO:0008603), qualified as loss of function. GO:0008603 is a molecular function from the Gene Ontology. ⇓ LOSS OF FUNCTION
Show evidence (2 references)
PMID:10973256 SUPPORT Human Clinical
"In CNC families mapping to 17q, we detected loss of heterozygosity (LOH) in the vicinity of the gene (PRKAR1A) encoding protein kinase A regulatory subunit 1-alpha (RIalpha), including a polymorphic site within its 5' region."
Somatic loss of the retained allele in tumor tissue is what makes this a biallelic state rather than a haploinsufficient one. The PKA-activity evidence below establishes the functional consequence but not the allelic state.
PMID:10973256 SUPPORT Human Clinical
"Analysis of PKA activity in CNC tumours demonstrated a decreased basal activity, but an increase in cAMP-stimulated activity compared with non-CNC tumours."
The direct measurement of the altered PKA response in Carney complex tumours, which is exactly the state this node asserts — and specifically not a simple increase in basal kinase activity.
Multiple Neoplasia and Paradoxical Endocrine Overactivity
The clinical output: spotty skin pigmentation, cardiac and cutaneous myxomas, endocrine overactivity — primary pigmented nodular adrenocortical disease causing ACTH-independent Cushing syndrome, growth-hormone-secreting pituitary adenoma, thyroid and testicular tumors — and psammomatous melanotic schwannoma. Lesions are characteristically multiple and recurrent, and cardiac myxomas may be multichambered and recur after resection, which is why surveillance continues lifelong rather than ending after successful surgery. The resemblance to McCune-Albright syndrome, which reaches constitutive cAMP signalling by a somatic activating GNAS variant instead, is mechanistic rather than coincidental and was part of the reasoning that identified PRKAR1A.
Show evidence (2 references)
PMID:10973256 SUPPORT Human Clinical
"Carney complex (CNC) is a multiple neoplasia syndrome characterized by spotty skin pigmentation, cardiac and other myxomas, endocrine tumours and psammomatous melanotic schwannomas."
Defines the four-component tumor spectrum that this consequence node asserts.
PMID:10973256 SUPPORT Human Clinical
"Because of its similarities to the McCune-Albright syndrome and other features, such as paradoxical responses to endocrine signals, genes implicated in cyclic nucleotide-dependent signalling have been considered candidates for causing CNC (ref. 10)."
Documents both the paradoxical endocrine responses and the mechanistic parallel with McCune-Albright syndrome asserted here.

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Carney Complex Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.

Phenotypes

6
Cardiac Myxoma Cardiovascular HP:0011672 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cardiac myxoma (HP:0011672). HP:0011672 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:10973256 SUPPORT Human Clinical
"Carney complex (CNC) is a multiple neoplasia syndrome characterized by spotty skin pigmentation, cardiac and other myxomas, endocrine tumours and psammomatous melanotic schwannomas."
Names cardiac myxoma as a defining component of the syndrome.
PMID:20301463 SUPPORT Other
"Cardiac myxomas occur at a young age, may occur in any or all cardiac chambers, and can manifest as intracardiac obstruction of blood flow, embolic phenomenon, and/or heart failure."
GeneReviews Clinical Characteristics section, giving the young onset, the any-chamber distribution and the three mechanisms of harm — which together are why echocardiographic surveillance starts in childhood and never stops.
Multiple Lentigines Dermatologic HP:0001003 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Multiple lentigines (HP:0001003). HP:0001003 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:10973256 SUPPORT Human Clinical
"Carney complex (CNC) is a multiple neoplasia syndrome characterized by spotty skin pigmentation, cardiac and other myxomas, endocrine tumours and psammomatous melanotic schwannomas."
Names spotty skin pigmentation as a defining feature.
PMID:20301463 SUPPORT Other
"Pale brown to black lentigines are the most common presenting feature of CNC and typically increase in number at puberty."
GeneReviews Clinical Characteristics section, identifying lentigines as the commonest presenting feature and giving their pubertal timing.
Schwannoma Neurologic HP:0100008 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Schwannoma (HP:0100008). HP:0100008 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:10973256 SUPPORT Human Clinical
"Carney complex (CNC) is a multiple neoplasia syndrome characterized by spotty skin pigmentation, cardiac and other myxomas, endocrine tumours and psammomatous melanotic schwannomas."
Names psammomatous melanotic schwannoma as a defining component.
PMID:20301463 SUPPORT Other
"Psammomatous melanotic schwannoma (PMS), a rare tumor of the nerve sheath, occurs in an estimated 10% of affected individuals."
GeneReviews Clinical Characteristics section, quantifying the frequency of this near-pathognomonic tumor at roughly 10%.
Primary Hypercortisolism Endocrine HP:0001579 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Primary hypercortisolism (HP:0001579). HP:0001579 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301463 SUPPORT Other
"Primary pigmented nodular adrenocortical disease (PPNAD), which causes Cushing syndrome, is the most frequently observed endocrine tumor in CNC, occurring in approximately 25% of affected individuals."
GeneReviews Clinical Characteristics section, naming the lesion, its endocrine consequence and its frequency.
Thyroid Nodule Endocrine HP:0025388 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Thyroid nodule (HP:0025388). HP:0025388 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301463 SUPPORT Other
"Up to 75% of individuals with CNC have multiple thyroid nodules, most of which are nonfunctioning thyroid follicular adenomas."
GeneReviews Clinical Characteristics section, quantifying frequency and establishing that most nodules are benign and nonfunctioning.
Large Cell Calcifying Sertoli Cell Tumor Reproductive HP:0100619 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Sertoli cell neoplasm (HP:0100619). HP:0100619 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301463 SUPPORT Other
"Large cell calcifying Sertoli cell tumors (LCCSCTs) are observed in one third of affected males within the first decade and in most adult males."
GeneReviews Clinical Characteristics section, giving the frequency in both childhood and adulthood and the basis for annual testicular ultrasound from childhood in males.
🧬

Genetic Associations

1
PRKAR1A
Gene: PRKAR1A hgnc:9388 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is PRKAR1A (hgnc:9388). hgnc:9388 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
Show evidence (1 reference)
PMID:10973256 SUPPORT Human Clinical
"Analysis of additional cases revealed the same mutation in a sporadic case of CNC, and different mutations in three other families, including one with isolated inherited cardiac myxomas."
Documents the allelic spectrum, including a de novo sporadic case and a family with an isolated cardiac-myxoma phenotype, which supports the variable expressivity curated in this entry.
💊

Medical Actions

3
Lifelong Echocardiographic Surveillance for Cardiac Myxoma
Action: Echocardiography TestNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Echocardiography Test (NCIT:C16525). NCIT:C16525 is a clinical intervention from the NCI Thesaurus. NCIT:C16525
The single most consequential intervention in Carney complex. Because myxomas arise at a young age, in any chamber, and recur after excision, echocardiography begins in childhood and moves to twice-yearly in anyone who has already had one excised. Surveillance does not end after a successful operation — recurrence in retained tissue is expected, which is the clinical expression of independent second hits.
Mechanism Target:
INHIBITS Multiple Neoplasia and Paradoxical Endocrine Overactivity — Surveillance acts on the consequence node by detecting myxomas before they obstruct, embolise or cause heart failure; it does not prevent their formation.
Show evidence (1 reference)
PMID:20301463 SUPPORT Other
"Echocardiography annually beginning in childhood, biannually for those with a history of excised myxoma"
GeneReviews Management section, giving the surveillance interval and its escalation after a first myxoma — the schedule this entry curates as lifelong.
Surgical Excision of Myxomas and Endocrine Tumors
Action: Surgical ProcedureNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Surgical Procedure (NCIT:C15329). NCIT:C15329 is a clinical intervention from the NCI Thesaurus. NCIT:C15329
Cardiac myxomas are removed by open heart surgery; cutaneous and mammary myxomas are excised locally. Endocrine disease is managed organ by organ, including bilateral adrenalectomy for the Cushing syndrome of PPNAD. In boys with aggressive Sertoli cell tumors, orchiectomy is done specifically to prevent premature epiphyseal fusion and central precocious puberty rather than for malignant potential.
Mechanism Target:
INHIBITS Multiple Neoplasia and Paradoxical Endocrine Overactivity — Resection removes established lesions and their hormonal output; the germline lesion and the risk of further tumors are unchanged.
Show evidence (2 references)
PMID:20301463 SUPPORT Other
"Surgical excision via open heart surgery for cardiac myxomas; surgical excision of cutaneous and mammary myxomas; bilateral adrenalectomy for Cushing syndrome; transsphenoidal surgery for pituitary adenoma"
GeneReviews Management section, giving the organ-by-organ surgical approach across the complex.
PMID:20301463 SUPPORT Other
"orchiectomy for boys with aggressive LCCSCT and gynecomastia to avoid premature epiphyseal fusion and induction of central precocious puberty"
GeneReviews Management section. The stated indication is endocrine consequence rather than malignancy, which is why this is a growth-related decision in childhood.
Endocrine Surveillance from Adolescence
Action: Supportive CareNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Supportive Care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. NCIT:C15747
Biochemical surveillance across the endocrine axes the complex affects — cortisol, IGF-1, thyroid and gonadal — beginning in adolescence, with growth rate and pubertal staging monitored at every visit in children.
Mechanism Target:
INHIBITS Multiple Neoplasia and Paradoxical Endocrine Overactivity — Detects hormonal overactivity before it produces irreversible endocrine consequences; acts on the consequence node, not on the lesion.
Show evidence (2 references)
PMID:20301463 SUPPORT Other
"urinary free cortisol levels annually beginning in adolescence with diurnal cortisol levels, dexamethasome stimulation test, and adrenal CT as needed; annual serum IGF-1 beginning in adolescence"
GeneReviews Management section, giving the adrenal and somatotroph surveillance analytes and their start age.
PMID:20301463 SUPPORT Other
"monitor growth rate and pubertal staging at each visit and testicular ultrasound annually in males beginning in childhood"
GeneReviews Management section, giving the paediatric surveillance that exists because the Sertoli cell tumor acts on growth and puberty.
🔬

Diagnosis

2
Clinical Diagnostic Criteria for Carney Complex
A clinical diagnosis rests on two or more major diagnostic criteria drawn from the pigmentary, myxomatous, endocrine and schwannoma features. The median age at diagnosis is 20 years, so most patients are identified in adolescence or early adulthood.
Clinical Evaluation NCIT:C124351 NCI Thesaurus (NCIT)
Results: Two or more major criteria establish the clinical diagnosis and prompt confirmatory PRKAR1A testing.
Show evidence (2 references)
PMID:20301463 SUPPORT Other
"The clinical diagnosis of CNC is established in a proband with two or more major diagnostic criteria."
GeneReviews Diagnosis/Testing section, giving the clinical diagnostic threshold.
PMID:20301463 SUPPORT Other
"The median age of diagnosis is 20 years."
GeneReviews Clinical Characteristics section, giving the age at which the diagnosis is typically made — the practical target that surveillance of at-risk relatives aims to beat.
Molecular Genetic Testing for PRKAR1A
A heterozygous germline PRKAR1A pathogenic variant establishes the molecular diagnosis. Where testing is uninformative — expected in the subset of families mapping to the second locus at 2p16 — GeneReviews recommends surveillance of at-risk relatives on the basis of their 50% prior risk rather than discharging them.
Genetic Testing NCIT:C15709 NCI Thesaurus (NCIT)
Results: A heterozygous germline pathogenic PRKAR1A variant confirms the diagnosis; an uninformative result does not exclude it.
Show evidence (2 references)
PMID:20301463 SUPPORT Other
"The molecular diagnosis can be established in a proband with suggestive findings and a heterozygous germline pathogenic variant in PRKAR1A identified by molecular genetic testing."
GeneReviews Diagnosis/Testing section, stating the confirmatory molecular test.
PMID:20301463 SUPPORT Other
"Surveillance is recommended for individuals at 50% risk when molecular genetic testing is not possible or is not informative."
GeneReviews Evaluation of Relatives at Risk. This is the clinically important corollary of the syndrome's locus heterogeneity: a negative or unavailable PRKAR1A result does not release an at-risk relative from surveillance.
🔬

Clinical Trials

1
NCT00668291 NOT_APPLICABLE COMPLETED
Completed French cohort study assessing the clinical, genetic, biological and imaging course of Carney complex and primary pigmented nodular adrenocortical disease, with PRKAR1A genotyping in an isolated-myxoma comparison cohort.
Target Phenotypes: Primary pigmented nodular adrenocortical disease HP:0001579 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Primary pigmented nodular adrenocortical disease, annotated with Primary hypercortisolism (HP:0001579). HP:0001579 is a phenotype from the Human Phenotype Ontology. Cardiac myxoma HP:0011672 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Cardiac myxoma (HP:0011672). HP:0011672 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
clinicaltrials:NCT00668291 SUPPORT Human Clinical
"Cohort CNC-PPNAD will be investigated with clinical, genetic, biological and imaging work-up every year during 3 years."
Registry record for the completed prospective CNC/PPNAD natural-history cohort with annual multimodal assessment.
{ }

Source YAML

click to show
name: Carney Complex
creation_date: "2026-08-23T00:00:00Z"
category: Mendelian
categories:
- Hereditary Cancer Syndrome
- Cancer Predisposition Syndrome
- Endocrine Neoplasia
parents:
- hereditary cancer-predisposing syndrome
disease_term:
  preferred_term: Carney complex
  term:
    id: MONDO:0015285
    label: Carney complex
synonyms:
- CNC
- LAMB syndrome
- NAME syndrome
- Carney syndrome
description: >-
  Carney complex is an autosomal dominant multiple neoplasia syndrome defined by
  the combination of spotty skin pigmentation (lentigines and blue naevi),
  cardiac and extracardiac myxomas, endocrine overactivity, and psammomatous
  melanotic schwannoma. Most cases are caused by germline inactivating variants
  in PRKAR1A at 17q22-24, encoding the type I-alpha regulatory subunit (RIalpha)
  of protein kinase A; a second locus at 2p16 accounts for the remainder.
  Mechanistically the syndrome is a tumor suppressor two-hit disorder in which
  the suppressor is a brake on a second-messenger pathway rather than on the cell
  cycle. RIalpha binds and inhibits the PKA catalytic subunits until cyclic AMP
  displaces it; losing RIalpha therefore does not raise basal kinase activity so
  much as remove the restraint on cAMP-stimulated activity, and this is what
  measurement in Carney complex tumours shows — decreased basal PKA activity but
  increased cAMP-stimulated activity relative to non-Carney tumours. That
  signature explains the syndrome's most distinctive clinical trait, the
  paradoxical responses to endocrine signals seen in primary pigmented nodular
  adrenocortical disease, where dexamethasone raises rather than suppresses
  cortisol. Two-hit architecture is directly evidenced: loss of heterozygosity
  in the vicinity of PRKAR1A in 17q-linked families is what localized the gene.
  Cardiac myxoma is the principal cause of death and can occur at any age and in
  any chamber, which drives lifelong echocardiographic surveillance.
inheritance:
- name: Autosomal dominant
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  penetrance: INCOMPLETE
  expressivity: VARIABLE
  description: >-
    Carney complex is inherited as an autosomal dominant trait with variable
    expressivity: which components of the complex appear differs between
    families and between affected members of one family, and at least two loci
    are involved. Sporadic cases arising from de novo variants are well
    documented.
  evidence:
  - reference: PMID:10973256
    reference_title: Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      CNC is inherited as an autosomal dominant trait and the genes responsible
      have been mapped to 2p16 and 17q22-24 (refs 6, 7).
    explanation: >-
      States the inheritance pattern and the genetic heterogeneity of the
      syndrome.
  - reference: PMID:20301463
    reference_title: "Carney Complex."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Approximately 70% of individuals diagnosed with CNC have an affected
      parent; approximately 30% have a de novo pathogenic variant.
    explanation: >-
      GeneReviews Genetic Counseling section. The de novo rate is high enough
      that a negative family history carries little weight against the
      diagnosis. Evidence source is OTHER because GeneReviews is an
      expert-authored review rather than a primary study.
  - reference: PMID:20301463
    reference_title: "Carney Complex."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Each child of an individual with CNC has a 50% chance of inheriting the
      pathogenic variant.
    explanation: >-
      GeneReviews Genetic Counseling section: the transmission risk to
      offspring.
pathophysiology:
- name: Germline PRKAR1A First-Hit Inactivation
  conforms_to: "germline_two_hit_tumor_predisposition#Constitutional First-Hit Tumor Suppressor Inactivation"
  description: >-
    A heterozygous inactivating variant in PRKAR1A, encoding the PKA type I-alpha
    regulatory subunit RIalpha, is present constitutionally. Candidate-gene
    reasoning arrived at cyclic-nucleotide signalling before the gene was found,
    from the syndrome's resemblance to McCune-Albright syndrome and from its
    paradoxical endocrine responses. An identical coding-region variant was found
    in three unrelated kindreds and again in a sporadic case, with distinct
    variants in further families including one with isolated inherited cardiac
    myxomas.
  role: trigger
  biological_scale: MOLECULAR
  gene:
    preferred_term: PRKAR1A
    modifier: DECREASED
    term:
      id: hgnc:9388
      label: PRKAR1A
  genetic_context:
    gene:
      preferred_term: PRKAR1A
      term:
        id: hgnc:9388
        label: PRKAR1A
    variant_origin: GERMLINE
    allelic_hit_role: FIRST_HIT
    allelic_events:
    - PATHOGENIC_VARIANT
    zygosity: HETEROZYGOUS
    functional_impact_category: LOSS_OF_FUNCTION
    description: >-
      Constitutional heterozygous inactivating PRKAR1A variant; a recurrent
      coding-region variant was shared by three unrelated kindreds and one
      sporadic case.
  evidence:
  - reference: PMID:10973256
    reference_title: Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We subsequently identified three unrelated kindreds with an identical
      mutation in the coding region of PRKAR1A.
    explanation: >-
      Identifies the recurrent germline PRKAR1A lesion in Carney complex
      families.
  - reference: PMID:10973256
    reference_title: Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We conclude that germline mutations in PRKAR1A, an apparent
      tumour-suppressor gene, are responsible for the CNC phenotype in a subset
      of patients with this disease.
    explanation: >-
      Establishes PRKAR1A as a tumor suppressor and the cause of the syndrome in
      a subset of patients, which places this disorder in the two-hit class.
      Note the authors' own qualifiers ("apparent", "a subset") are preserved.
  downstream:
  - target: Somatic PRKAR1A Second-Hit Loss of Heterozygosity
    description: >-
      A somatic event removing the retained wild-type allele completes RIalpha
      loss in the tumor-forming cell.

- name: Somatic PRKAR1A Second-Hit Loss of Heterozygosity
  conforms_to: "germline_two_hit_tumor_predisposition#Somatic Second-Hit Inactivation of the Wild-Type Allele"
  description: >-
    Tumors from 17q-linked Carney complex families show loss of heterozygosity in
    the vicinity of PRKAR1A, including at a polymorphic site in its 5' region.
    Detecting that loss is what localized the gene, and it is the direct evidence
    that the syndrome follows the classical two-hit architecture rather than
    acting through haploinsufficiency alone.
  role: amplifier
  biological_scale: MOLECULAR
  genetic_context:
    gene:
      preferred_term: PRKAR1A
      term:
        id: hgnc:9388
        label: PRKAR1A
    variant_origin: SOMATIC
    allelic_hit_role: SECOND_HIT
    allelic_events:
    - LOSS_OF_HETEROZYGOSITY
    functional_impact_category: LOSS_OF_FUNCTION
    description: >-
      Acquired loss of heterozygosity at the PRKAR1A locus in Carney complex
      tumor tissue.
  evidence:
  - reference: PMID:10973256
    reference_title: Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In CNC families mapping to 17q, we detected loss of heterozygosity (LOH)
      in the vicinity of the gene (PRKAR1A) encoding protein kinase A regulatory
      subunit 1-alpha (RIalpha), including a polymorphic site within its 5'
      region.
    explanation: >-
      The direct demonstration of somatic loss of heterozygosity at the locus,
      which is the second hit this node asserts.
  downstream:
  - target: Loss of RIalpha Restraint on cAMP-Stimulated PKA Signaling
    description: >-
      With both alleles inactivated, the regulatory subunit no longer restrains
      the PKA catalytic subunits in response to cyclic AMP.

- name: Loss of RIalpha Restraint on cAMP-Stimulated PKA Signaling
  conforms_to: "germline_two_hit_tumor_predisposition#Biallelic Tumor Suppressor Inactivation in a Susceptible Cell"
  description: >-
    The rate-limiting state. RIalpha holds the PKA catalytic subunits inactive
    until displaced by cyclic AMP; losing it therefore changes the shape of the
    response rather than simply raising output. Carney complex tumours show
    decreased basal PKA activity but increased cAMP-stimulated activity relative
    to non-Carney tumours — an inversion of the normal relationship between
    stimulus and kinase output that is the biochemical correlate of the
    syndrome's paradoxical endocrine responses.
  role: central_effector
  biological_scale: MOLECULAR
  molecular_functions:
  - preferred_term: cAMP-dependent protein kinase regulator activity
    term:
      id: GO:0008603
      label: cAMP-dependent protein kinase regulator activity
    modifier: LOSS_OF_FUNCTION
  evidence:
  - reference: PMID:10973256
    reference_title: Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In CNC families mapping to 17q, we detected loss of heterozygosity (LOH)
      in the vicinity of the gene (PRKAR1A) encoding protein kinase A regulatory
      subunit 1-alpha (RIalpha), including a polymorphic site within its 5'
      region.
    explanation: >-
      Somatic loss of the retained allele in tumor tissue is what makes this a
      biallelic state rather than a haploinsufficient one. The PKA-activity
      evidence below establishes the functional consequence but not the allelic
      state.
  - reference: PMID:10973256
    reference_title: Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Analysis of PKA activity in CNC tumours demonstrated a decreased basal
      activity, but an increase in cAMP-stimulated activity compared with
      non-CNC tumours.
    explanation: >-
      The direct measurement of the altered PKA response in Carney complex
      tumours, which is exactly the state this node asserts — and specifically
      not a simple increase in basal kinase activity.
  downstream:
  - target: Multiple Neoplasia and Paradoxical Endocrine Overactivity
    description: >-
      Unrestrained cAMP-stimulated PKA signalling drives tumor formation and
      hormone excess in the affected lineages.

- name: Multiple Neoplasia and Paradoxical Endocrine Overactivity
  conforms_to: "germline_two_hit_tumor_predisposition#Early-Onset, Multifocal, and Bilateral Tumor Spectrum"
  description: >-
    The clinical output: spotty skin pigmentation, cardiac and cutaneous
    myxomas, endocrine overactivity — primary pigmented nodular adrenocortical
    disease causing ACTH-independent Cushing syndrome, growth-hormone-secreting
    pituitary adenoma, thyroid and testicular tumors — and psammomatous melanotic
    schwannoma. Lesions are characteristically multiple and recurrent, and
    cardiac myxomas may be multichambered and recur after resection, which is why
    surveillance continues lifelong rather than ending after successful surgery.
    The resemblance to McCune-Albright syndrome, which reaches constitutive cAMP
    signalling by a somatic activating GNAS variant instead, is mechanistic
    rather than coincidental and was part of the reasoning that identified
    PRKAR1A.
  role: consequence
  biological_scale: ORGANISM
  evidence:
  - reference: PMID:10973256
    reference_title: Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Carney complex (CNC) is a multiple neoplasia syndrome characterized by
      spotty skin pigmentation, cardiac and other myxomas, endocrine tumours and
      psammomatous melanotic schwannomas.
    explanation: >-
      Defines the four-component tumor spectrum that this consequence node
      asserts.
  - reference: PMID:10973256
    reference_title: Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Because of its similarities to the McCune-Albright syndrome and other
      features, such as paradoxical responses to endocrine signals, genes
      implicated in cyclic nucleotide-dependent signalling have been considered
      candidates for causing CNC (ref. 10).
    explanation: >-
      Documents both the paradoxical endocrine responses and the mechanistic
      parallel with McCune-Albright syndrome asserted here.
phenotypes:
- category: Cardiovascular
  name: Cardiac Myxoma
  description: >-
    Myxomas may arise in any cardiac chamber, may be multiple, and recur after
    resection; they are the principal cause of mortality in Carney complex,
    through embolism, obstruction or operative risk.
  phenotype_term:
    preferred_term: Cardiac myxoma
    term:
      id: HP:0011672
      label: Cardiac myxoma
  evidence:
  - reference: PMID:10973256
    reference_title: Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Carney complex (CNC) is a multiple neoplasia syndrome characterized by
      spotty skin pigmentation, cardiac and other myxomas, endocrine tumours and
      psammomatous melanotic schwannomas.
    explanation: >-
      Names cardiac myxoma as a defining component of the syndrome.
  - reference: PMID:20301463
    reference_title: "Carney Complex."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Cardiac myxomas occur at a young age, may occur in any or all cardiac
      chambers, and can manifest as intracardiac obstruction of blood flow,
      embolic phenomenon, and/or heart failure.
    explanation: >-
      GeneReviews Clinical Characteristics section, giving the young onset, the
      any-chamber distribution and the three mechanisms of harm — which
      together are why echocardiographic surveillance starts in childhood and
      never stops.
- category: Dermatologic
  name: Multiple Lentigines
  description: >-
    Spotty skin pigmentation — lentigines with a characteristic distribution
    including the vermilion border of the lips, conjunctiva and genital mucosa,
    often with blue naevi — which is typically the earliest recognizable feature.
  phenotype_term:
    preferred_term: Multiple lentigines
    term:
      id: HP:0001003
      label: Multiple lentigines
  evidence:
  - reference: PMID:10973256
    reference_title: Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Carney complex (CNC) is a multiple neoplasia syndrome characterized by
      spotty skin pigmentation, cardiac and other myxomas, endocrine tumours and
      psammomatous melanotic schwannomas.
    explanation: >-
      Names spotty skin pigmentation as a defining feature.
  - reference: PMID:20301463
    reference_title: "Carney Complex."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Pale brown to black lentigines are the most common presenting feature of
      CNC and typically increase in number at puberty.
    explanation: >-
      GeneReviews Clinical Characteristics section, identifying lentigines as
      the commonest presenting feature and giving their pubertal timing.
- category: Neurologic
  name: Schwannoma
  description: >-
    Psammomatous melanotic schwannoma, a distinctive nerve sheath tumor that is
    near-specific to Carney complex and may be multiple; a minority behave
    malignantly.
  phenotype_term:
    preferred_term: Schwannoma
    term:
      id: HP:0100008
      label: Schwannoma
  evidence:
  - reference: PMID:10973256
    reference_title: Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Carney complex (CNC) is a multiple neoplasia syndrome characterized by
      spotty skin pigmentation, cardiac and other myxomas, endocrine tumours and
      psammomatous melanotic schwannomas.
    explanation: >-
      Names psammomatous melanotic schwannoma as a defining component.
  - reference: PMID:20301463
    reference_title: "Carney Complex."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Psammomatous melanotic schwannoma (PMS), a rare tumor of the nerve sheath,
      occurs in an estimated 10% of affected individuals.
    explanation: >-
      GeneReviews Clinical Characteristics section, quantifying the frequency of
      this near-pathognomonic tumor at roughly 10%.
- category: Endocrine
  name: Primary Hypercortisolism
  description: >-
    Primary pigmented nodular adrenocortical disease (PPNAD) causes an
    ACTH-independent Cushing syndrome and is the commonest endocrine tumor of
    the complex, affecting about a quarter of patients. It is the setting of the
    paradoxical dexamethasone response that follows from the altered PKA
    dose-response curve curated in this entry's pathophysiology.
  phenotype_term:
    preferred_term: Primary hypercortisolism
    term:
      id: HP:0001579
      label: Primary hypercortisolism
  evidence:
  - reference: PMID:20301463
    reference_title: "Carney Complex."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Primary pigmented nodular adrenocortical disease (PPNAD), which causes
      Cushing syndrome, is the most frequently observed endocrine tumor in CNC,
      occurring in approximately 25% of affected individuals.
    explanation: >-
      GeneReviews Clinical Characteristics section, naming the lesion, its
      endocrine consequence and its frequency.
- category: Endocrine
  name: Thyroid Nodule
  description: >-
    Multiple thyroid nodules occur in up to three quarters of patients and are
    mostly nonfunctioning follicular adenomas, which is why annual thyroid
    ultrasound is part of surveillance.
  phenotype_term:
    preferred_term: Thyroid nodule
    term:
      id: HP:0025388
      label: Thyroid nodule
  evidence:
  - reference: PMID:20301463
    reference_title: "Carney Complex."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Up to 75% of individuals with CNC have multiple thyroid nodules, most of
      which are nonfunctioning thyroid follicular adenomas.
    explanation: >-
      GeneReviews Clinical Characteristics section, quantifying frequency and
      establishing that most nodules are benign and nonfunctioning.
- category: Reproductive
  name: Large Cell Calcifying Sertoli Cell Tumor
  description: >-
    A characteristic testicular tumor of the complex, present in a third of
    affected boys in the first decade and in most adult males. Its endocrine
    activity is what makes it clinically urgent in childhood — it can drive
    gynaecomastia and premature epiphyseal fusion.
  phenotype_term:
    preferred_term: Sertoli cell neoplasm
    term:
      id: HP:0100619
      label: Sertoli cell neoplasm
  evidence:
  - reference: PMID:20301463
    reference_title: "Carney Complex."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Large cell calcifying Sertoli cell tumors (LCCSCTs) are observed in one
      third of affected males within the first decade and in most adult males.
    explanation: >-
      GeneReviews Clinical Characteristics section, giving the frequency in both
      childhood and adulthood and the basis for annual testicular ultrasound
      from childhood in males.
genetic:
- name: PRKAR1A
  gene_term:
    preferred_term: PRKAR1A
    term:
      id: hgnc:9388
      label: PRKAR1A
  relationship_type: CAUSATIVE
  notes: >-
    PRKAR1A at 17q22-24 encodes the PKA type I-alpha regulatory subunit RIalpha.
    Germline inactivating variants cause Carney complex in a subset of patients;
    tumors additionally show loss of heterozygosity at the locus. A second,
    separately mapped locus at 2p16 accounts for the remaining families.
  evidence:
  - reference: PMID:10973256
    reference_title: Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Analysis of additional cases revealed the same mutation in a sporadic case
      of CNC, and different mutations in three other families, including one
      with isolated inherited cardiac myxomas.
    explanation: >-
      Documents the allelic spectrum, including a de novo sporadic case and a
      family with an isolated cardiac-myxoma phenotype, which supports the
      variable expressivity curated in this entry.
references:
- reference: PMID:20301463
  title: "Carney Complex."
  tags:
  - GeneReviews
treatments:
- name: Lifelong Echocardiographic Surveillance for Cardiac Myxoma
  notes: >-
    Curated under `treatments:` as a management intervention, not as a claim
    that imaging or biochemistry is itself therapeutic. In a two-hit
    predisposition syndrome the second hit cannot be prevented, so the only
    available lever is stage at detection: surveillance is the intervention
    that converts an unavoidable tumor into a resectable one. Where a
    `target_mechanisms` link is present it points at the clinical-outcome node
    for that reason, and never at an upstream mechanistic node.
  description: >-
    The single most consequential intervention in Carney complex. Because
    myxomas arise at a young age, in any chamber, and recur after excision,
    echocardiography begins in childhood and moves to twice-yearly in anyone
    who has already had one excised. Surveillance does not end after a
    successful operation — recurrence in retained tissue is expected, which is
    the clinical expression of independent second hits.
  therapeutic_modality: DEVICE
  treatment_term:
    preferred_term: Echocardiography Test
    term:
      id: NCIT:C16525
      label: Echocardiography Test
  target_mechanisms:
  - target: Multiple Neoplasia and Paradoxical Endocrine Overactivity
    treatment_effect: INHIBITS
    description: >-
      Surveillance acts on the consequence node by detecting myxomas before
      they obstruct, embolise or cause heart failure; it does not prevent their
      formation.
  evidence:
  - reference: PMID:20301463
    reference_title: "Carney Complex."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Echocardiography annually beginning in childhood, biannually for those
      with a history of excised myxoma
    explanation: >-
      GeneReviews Management section, giving the surveillance interval and its
      escalation after a first myxoma — the schedule this entry curates as
      lifelong.
- name: Surgical Excision of Myxomas and Endocrine Tumors
  description: >-
    Cardiac myxomas are removed by open heart surgery; cutaneous and mammary
    myxomas are excised locally. Endocrine disease is managed organ by organ,
    including bilateral adrenalectomy for the Cushing syndrome of PPNAD. In boys
    with aggressive Sertoli cell tumors, orchiectomy is done specifically to
    prevent premature epiphyseal fusion and central precocious puberty rather
    than for malignant potential.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: Surgical Procedure
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  target_mechanisms:
  - target: Multiple Neoplasia and Paradoxical Endocrine Overactivity
    treatment_effect: INHIBITS
    description: >-
      Resection removes established lesions and their hormonal output; the
      germline lesion and the risk of further tumors are unchanged.
  evidence:
  - reference: PMID:20301463
    reference_title: "Carney Complex."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Surgical excision via open heart surgery for cardiac myxomas; surgical
      excision of cutaneous and mammary myxomas; bilateral adrenalectomy for
      Cushing syndrome; transsphenoidal surgery for pituitary adenoma
    explanation: >-
      GeneReviews Management section, giving the organ-by-organ surgical
      approach across the complex.
  - reference: PMID:20301463
    reference_title: "Carney Complex."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      orchiectomy for boys with aggressive LCCSCT and gynecomastia to avoid
      premature epiphyseal fusion and induction of central precocious puberty
    explanation: >-
      GeneReviews Management section. The stated indication is endocrine
      consequence rather than malignancy, which is why this is a growth-related
      decision in childhood.
- name: Endocrine Surveillance from Adolescence
  description: >-
    Biochemical surveillance across the endocrine axes the complex affects —
    cortisol, IGF-1, thyroid and gonadal — beginning in adolescence, with
    growth rate and pubertal staging monitored at every visit in children.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  target_mechanisms:
  - target: Multiple Neoplasia and Paradoxical Endocrine Overactivity
    treatment_effect: INHIBITS
    description: >-
      Detects hormonal overactivity before it produces irreversible endocrine
      consequences; acts on the consequence node, not on the lesion.
  evidence:
  - reference: PMID:20301463
    reference_title: "Carney Complex."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      urinary free cortisol levels annually beginning in adolescence with
      diurnal cortisol levels, dexamethasome stimulation test, and adrenal CT as
      needed; annual serum IGF-1 beginning in adolescence
    explanation: >-
      GeneReviews Management section, giving the adrenal and somatotroph
      surveillance analytes and their start age.
  - reference: PMID:20301463
    reference_title: "Carney Complex."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      monitor growth rate and pubertal staging at each visit and testicular
      ultrasound annually in males beginning in childhood
    explanation: >-
      GeneReviews Management section, giving the paediatric surveillance that
      exists because the Sertoli cell tumor acts on growth and puberty.
diagnosis:
- name: Clinical Diagnostic Criteria for Carney Complex
  description: >-
    A clinical diagnosis rests on two or more major diagnostic criteria drawn
    from the pigmentary, myxomatous, endocrine and schwannoma features. The
    median age at diagnosis is 20 years, so most patients are identified in
    adolescence or early adulthood.
  diagnosis_term:
    preferred_term: Clinical Evaluation
    term:
      id: NCIT:C124351
      label: Clinical Evaluation
  results: >-
    Two or more major criteria establish the clinical diagnosis and prompt
    confirmatory PRKAR1A testing.
  evidence:
  - reference: PMID:20301463
    reference_title: "Carney Complex."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The clinical diagnosis of CNC is established in a proband with two or more
      major diagnostic criteria.
    explanation: >-
      GeneReviews Diagnosis/Testing section, giving the clinical diagnostic
      threshold.
  - reference: PMID:20301463
    reference_title: "Carney Complex."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The median age of diagnosis is 20 years.
    explanation: >-
      GeneReviews Clinical Characteristics section, giving the age at which the
      diagnosis is typically made — the practical target that surveillance of
      at-risk relatives aims to beat.
- name: Molecular Genetic Testing for PRKAR1A
  description: >-
    A heterozygous germline PRKAR1A pathogenic variant establishes the molecular
    diagnosis. Where testing is uninformative — expected in the subset of
    families mapping to the second locus at 2p16 — GeneReviews recommends
    surveillance of at-risk relatives on the basis of their 50% prior risk
    rather than discharging them.
  diagnosis_term:
    preferred_term: Genetic Testing
    term:
      id: NCIT:C15709
      label: Genetic Testing
  results: >-
    A heterozygous germline pathogenic PRKAR1A variant confirms the diagnosis;
    an uninformative result does not exclude it.
  evidence:
  - reference: PMID:20301463
    reference_title: "Carney Complex."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The molecular diagnosis can be established in a proband with suggestive
      findings and a heterozygous germline pathogenic variant in PRKAR1A
      identified by molecular genetic testing.
    explanation: >-
      GeneReviews Diagnosis/Testing section, stating the confirmatory molecular
      test.
  - reference: PMID:20301463
    reference_title: "Carney Complex."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Surveillance is recommended for individuals at 50% risk when molecular
      genetic testing is not possible or is not informative.
    explanation: >-
      GeneReviews Evaluation of Relatives at Risk. This is the clinically
      important corollary of the syndrome's locus heterogeneity: a negative or
      unavailable PRKAR1A result does not release an at-risk relative from
      surveillance.
clinical_trials:
- name: NCT00668291
  phase: NOT_APPLICABLE
  status: COMPLETED
  description: >-
    Completed French cohort study assessing the clinical, genetic, biological
    and imaging course of Carney complex and primary pigmented nodular
    adrenocortical disease, with PRKAR1A genotyping in an isolated-myxoma
    comparison cohort.
  target_phenotypes:
  - preferred_term: Primary pigmented nodular adrenocortical disease
    term:
      id: HP:0001579
      label: Primary hypercortisolism
  - preferred_term: Cardiac myxoma
    term:
      id: HP:0011672
      label: Cardiac myxoma
  evidence:
  - reference: clinicaltrials:NCT00668291
    reference_title: Assessment of the Clinical Symptoms of the Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the CARNEY Complex (CNC).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Cohort CNC-PPNAD will be investigated with clinical, genetic, biological and imaging work-up every year during 3 years.
    explanation: >-
      Registry record for the completed prospective CNC/PPNAD natural-history
      cohort with annual multimodal assessment.
📚

References & Deep Research

References

1
Carney Complex.
No top-level findings curated for this source.